Alzheimer's drug trials to take different approach
Timing might be everything when it comes to treating Alzheimer's disease, according to research being presented on Monday at a meeting of the American Neurological Association in Boston.
There is no cure for the disease, which affects more than 5 million people in the country, and numbers are expected to triple by 2050.
Researchers will discuss findings on two large drug trials. Results announced last summer found that they failed to improve cognition or daily functioning compared with a placebo. The bapineuzumab and solanezumab therapies were done on patients with mild to moderate dementia. The drugs target beta amyloid, a protein in the brain believed to cause the disease.
“We think we've been starting trials too late in the progression of the disease,” said Laurie Ryan of the National Institute on Aging.
Scientists are discovering mechanisms of the disease and how it progresses. A large study in the New England Journal of Medicine found that brain changes begin as early as 25 years before the onset of symptoms.
“I'm worried that we're intervening too late and with too little” of the drugs, said Reisa Sperling of Brigham and Women's Hospital in Boston.
Show commenting policy
TribLive commenting policy
- Met Museum of Art president to retire
- Move over, Mickey, here comes Crayola
- Girl struck by plane on beach succumbs
- Lone clinic in Miss. for abortions still stands
- UCLA inundated by burst pipe
- Surgeon general echoes warnings about skin cancer
- Obama’s many rules often violate statute
- N.H. kidnapping suspect held on $1M bail
- Appeals court upholds nation of origin labels for meat
- Swift action expected of VA’s new secretary
- Harshest sanctions yet target Russian finances, arms